Epigral Q1 FY27 results (Apr–Jun 2026) and concall

Chemicals · Concall AI · Call held 27 Jul 2026

Company page: Epigral share price, financials & guidance record

Epigral Limited reported resilient Q1 FY27 performance with 15% revenue growth and 25% adjusted PAT growth despite a challenging macroeconomic environment. The company announced a significant INR600 crore strategic capex for new Epoxy Resin & Formulations and a Multipurpose Plant, aiming for backward integration and long-term growth. While EBITDA margins saw some compression and ROCE declined, management remains optimistic about future growth and market absorption of new capacities.

You’re reading a preview. Opening the full call uses 1 concall credit.

What they filed

Q1 FY27: revenue up 16.1%, net profit down 37.9% against the same quarter last year.

₹ Cr · quarterly

Line item	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26	Q3 FY26	Q4 FY26	Q1 FY27
Revenue	626	645	628	607	587 −6%	597 −7%	736 +17%	705 +16%
Expenses	448	463	454	443	455	494	569	526
EBITDA	178	183	173	163	132 −26%	103 −44%	168 −3%	179 +10%
Margin	28%	28%	28%	27%	22%	17%	23%	25%
Other income	6	4	4	9	2	6	-1	5
Interest	27	0	12	23	22	11	16	7
Depreciation	32	33	34	42	42	43	42	43
Profit before tax	125	154	131	107	70 −44%	55 −64%	110 −16%	134 +25%
Tax rate	35%	33%	34%	-50%	26%	28%	26%	25%
Net profit	81	104	87	161	51 −37%	39 −62%	81 −7%	100 −38%
EPS	19.57	24.02	20.14	37.25	11.87	9.07	18.76	23.12

How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.

What they filed

More Chemicals earnings calls